CING and CINGW Related Headlines
Go Back- Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
- Cingulate posts wider Q2 loss as SG&A spending more than doubles
- Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
- Cingulate publishes PK data for ADHD drug CTx-1301 in CNS Drugs
- Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
- Cingulate publishes phase 3 ADHD drug trial results in peer-reviewed journal
- Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
- Cingulate added to Russell 3000E index
- Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
- Cingulate receives first U.S. patent for ADHD drug candidate CTx-1301
- Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
- FDA issues complete response letter for Cingulate's ADHD drug CTx-1301
- Cingulate Receives Complete Response Letter from FDA for CTx-1301
- Cingulate reports Q1 2026 results, raises $14.9M in cash
- Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
- Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
- Cingulate closes $12 million private placement at market price
- Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Cingulate appoints Bryan Downey as chief commercial officer
- Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
- Cingulate reports positive phase 3 trial results for ADHD drug CTx-1301
- Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
- Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
- FDA accepts Cingulate's drug application for ADHD treatment CTx-1301
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
CING and CINGW Related Press Releases
Go Back- Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
- Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
- Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
- Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
- Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
- Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
- Cingulate Receives Complete Response Letter from FDA for CTx-1301
- Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
- Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
- Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
- Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
- Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
